Reduced NOV expression correlates with disease progression in colorectal cancer and is associated with survival, invasion and chemoresistance of cancer cells by Li, Jun et al.
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2017
Reduced NOV expression correlates with disease progression in 
colorectal cancer and is associated with survival, invasion and 
chemoresistance of cancer cells
Jun Li1,2,3,*, Lin Ye2,*, Ping-Hui Sun2, Fei Zheng1,2, Fiona Ruge2, Lucy K. Satherley2, 
Yi Feng2, Huishan Zhao3, Guifang Du3, Tingting Wang1, Yao Yang1, Xuemei Ma1, 
Shan Cheng3, Xiaomei Yang3, Hefen Yu3, Xu Teng3, Yang Si3, Zhongtao Zhang1, 
Wen G. Jiang2,3
1Department of General Surgery, Beijing Key Laboratory of Cancer Invasion and Metastasis Research and National Clinical 
Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China 
2Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Heath Park, Cardiff, CF14 4XN, UK
3Cardiff University-Capital Medical University Joint Centre for Biomedical Research and Cancer Institute, Capital Medical 
University, Beijing, 100069, China
*These authors contributed equally to this work
Correspondence to: Zhongtao Zhang, email: zhangzht@medmail.com.cn 
Wen G. Jiang, email: JiangW@cf.ac.uk.
Keywords: NOV, colorectal cancer, JNK signalling pathways, proliferation, invasion
Received: May 06, 2016    Accepted: February 06, 2017    Published:
ABSTRACT
Aberrant expression of nephroblastoma overexpressed (NOV) has been evident 
in certain malignancies. In the current study, we aim to investigate the role played by 
NOV in colorectal cancer (CRC). NOV expression was determined in a cohort of 359 CRC 
tissues and 174 normal colorectal tissues. Its impact on CRC cells was investigated 
using in vitro NOV knockdown and overexpression models.  NOV transcripts were 
reduced in the CRC tumours compared with the paired adjacent normal colorectal 
tissues (p < 0.01) and was associated with distant metastases. NOV knockdown 
resulted in increased cell proliferation and invasion of RKO cells, whilst an opposite 
effect was seen in the HT115 NOV over expressing cells. A positive association 
between Caspase-3/-8 and NOV was seen in NOV knockdown and overexpression 
cell lines which contributed to the survival of serum deprived CRC cells. Further 
investigation showed that NOV regulated proliferation, survival and invasion through 
the JNK pathway. NOV knockdown in RKO cells reduced the responsiveness to 
5-Fluorouracil treatment, whilst overexpression in HT115 cells exhibited a contrasting 
effect. Taken together, NOV is reduced in CRC tumours and this is associated with 
disease progression. NOV inhibits the proliferation and invasion of CRC cells in vitro. 
Inhibition of proliferation is mediated by a regulation of Caspase-3/-8, via the JNK 
pathway, which has potential for predicting and preventing chemoresistance.
INTRODUCTION
Worldwide, colorectal cancer (CRC) is the second 
most commonly diagnosed cancer in females and third 
most commonly diagnosed cancer in males. An estimated 
1.2 million new cases, and 608,700 deaths due to CRC 
occurred in 2008 [1]. The highest incidence rates have 
been documented in Australia and New Zealand, Europe, 
and North America, whereas the lowest rates have been 
reported in Africa and South-Central Asia [1]. In China, 
the National Central Cancer Registry (NCCR) information 
indicated that colorectal cancer is the fourth most common 
cause of cancer death in women and fifth most common 
cause of cancer death in males [2]. 
The CCN family derives its name from an acronym 
of cysteine-rich protein 61 (CYR61), connective tissue 
growth factor (CTGF) and nephroblastoma overexpressed 
(NOV), which were the first three members discovered in 
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the early 1990’s [2–4]. These family members have since 
been renamed CCN1, 2 and 3 respectively, whilst the 
subsequently discovered other three family members; Wnt-
induced secreted protein-1 (WISP-1), WISP-2, and WISP-3 
are also now known as CCN4-6 respectively [5]. The CCNs 
are a group of matricellular signalling molecules, similar to 
other extracellular matrix proteins, involved in embryonic 
and postnatal development, angiogenesis, wound healing, 
fibrosis and inflammation [6–10]. 
An emerging role has been revealed for CCNs in a 
variety of malignancies. An elevated expression of CCN1 
protein has been indicated in invasive ductal carcinomas 
compared to ductal and lobular carcinoma in situ [11]. 
Our previous study revealed strong immunohistochemical 
staining of CCN4, CCN5 and CCN6 in normal colorectal 
epithelial cells, which was confined mostly to the cell 
membrane with a weaker staining present in the stroma. 
Membrane staining of CCN4, CCN5 and CCN6 were 
reduced in CRC tumours, with an elevated cytoplasmic 
staining of CCN4 and CCN6 but not CCN5 [12]. 
The NOV gene codes a protein (CCN3) of 357 
amino acids with an N-terminal secretory signal peptide 
and four functional domains: insulin-like growth factor 
binding protein (IGFBP), von Willebrand factor C 
(VWC), thrombospondin 1 (TSP-1) and a C-terminal 
cysteine knot (CT) [13]. Similar to other CCN members, 
overexpression of NOV has been observed in a number of 
solid tumours. Increased expression of NOV has been seen 
in prostate cancer cell lines compared with immortalized 
prostatic epithelial cell lines [14]. Primary musculoskeletal 
tumours that developed lung and/or bone metastases have 
been found to express a higher level of NOV [15]. NOV 
transcripts and protein levels have also been observed 
to be increased in cervical cancer tissues compared with 
corresponding normal tissues. The overexpression of 
CCN3 in cervical cancer was significantly associated 
with disease progression and lymph node metastasis [16]. 
A recent study reported elevated expression of NOV in 
a cohort of 126 CRC specimens [17]. However, the role 
played by NOV in colorectal cancer (CRC) remains 
unclear. The current study aims to investigate the role 
played by NOV in CRC.
RESULTS
The expression of NOV is reduced in CRC 
We first examined the expression of NOV in a cohort 
of CRC tissues, which included 359 CRC tumours and 
174 paired adjacent normal colorectal tissues, using real 
time PCR (Table 2). Reduced levels of NOV transcripts 
were seen in CRC tumours compared with its expression 
in the adjacent normal colorectal tissues (p = 0.0024). In 
analyses of two public available gene expression array 
data of human CRC tissue samples, reduced expression 
of NOV was also seen CRC tumours in comparison 
with normal colon tissue (Supplementary Figure 1A) or 
paired adjacent normal colon tissues (Supplementary 
Figure 1B). Reduced levels of NOV transcripts were seen 
in patients with distant metastases compared with that 
of patients who remained disease free (p = 0.012). The 
NOV transcript levels were found to be lower in rectal 
tumours in comparison with that seen in colon tumours 
(p = 0.0046). However, NOV transcripts were higher in 
tumours with more invasive growth/expansion which had 
invaded through the muscularis propria including T3 and 
T4 tumours, according to the TNM staging, in comparison 
to the expression in T1 and T2 tumours (p < 0.01). There 
were no correlations observed between NOV expression, 
tumour differentiation and lymphatic metastases. 
We further determined the expression of NOV 
protein in CRC tumours through immunochemical 
staining of NOV in 45 CRC tumours and 27 adjacent 
normal colorectal tissues (Figure 1). Intensive staining 
of NOV was observed in the cytoplasm of epithelial cells 
in normal colon tissues and the staining was reduced in 
CRC tissues. No differential expression of NOV was seen 
in the tumours of different T stages and also those that 
had either lymph node metastases or distant metastases 
(Supplementary Figure 2). Additional information is 
provided in Supplementary Table 1.
Impact of altered NOV expression on the 
adhesion, migration and invasion of CRC cells
To establish an in vitro cell line model for exploring 
the implications of NOV in CRC, we first examined the 
expression of NOV in a panel of CRC cell lines, i.e. 
RKO, HRT18, Caco-2 and HT115 using conventional 
PCR (Figure 2A). NOV was highly expressed by RKO 
cells compared with HRT18 and HT115 cell lines and 
it was absent from Caco2 cells. For assessing the effect 
of NOV on cellular functions, knockdown of NOV was 
performed in the RKO cells, while HT115 cells were used 
to generate a NOV overexpression model. Knockdown 
and overexpression of NOV in transfected cells was 
verified using RT-PCR (Figure 2B) and Western blotting 
(Figure 2C and 2D).
Following verification, we examined the influence 
on cell-matrix adhesion. Neither knockdown nor 
overexpression of NOV altered the adhesion of CRC cells 
compared with the controls (Supplementary Figure 3A). 
A wound healing assay was also employed to examine 
the impact of NOV on the migration of the CRC cell 
lines. No obvious change was observed (Supplementary 
Figure 3B). We then determined the invasiveness of 
those transfected cells: knockdown of NOV in RKO cells 
(RKONOVkd) resulted in an increased invasion compared 
with the control cells (RKOpEF) (p < 0.001) (Figure 2E), 
whilst the HT115NOVexp exhibited reduced cell invasiveness 
(p < 0.001) (Figure 2F). NOV has been reported to be 
able to repress the transcription and activation of matrix 
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metalloproteinases (MMPs), thus inhibiting the invasion of 
melanoma cells [18]. In order to investigate the activity of 
MMPs in these CRC cells, we used gelatin zymography to 
analyse their activity. Knockdown of NOV resulted in an 
increase of both active MMP2 and MMP9 in RKO cells, 
which was consistent with the enhanced invasiveness, 
while a reduced activation of MMP2 was seen in the 
HT115NOVexp cells (Figure 2G).
Effect of NOV knockdown and overexpression 
on cell proliferation and survival
RKONOVkd cells exhibited an increased proliferation 
compared with the control cells, while an inhibitory 
effect on proliferation was seen in the HT115NOVexp cells 
(Figure 3A). To analyse the molecular mechanisms 
underlying the effects on cellular functions in RKO 
NOV knockdown and HT115 NOV overexpression cells 
we used RT-PCR to detect the transcript level of cyclin: 
D1, D3, E, A and B1; cyclin-dependent kinase (CDK): 
1, 2, 4 and 6; CDK inhibitor (CKI): P15, P16, P21 and 
P27; G1/S checkpoint proteins: 53 and Rb; apoptosis 
signalling pathways regulators: caspase 3, 8, 9, Bcl-2, Fas 
and Survivin (data not shown). There was no differential 
expression seen within these genes, except in caspase-3, -8 
and -9. Caspase-3 and -8 were remarkably down-regulated 
as a result of NOV knockdown in RKO cells, while an 
up-regulation was seen in the HT115NOVexp cells (Figure 
3B). Corresponding changes were seen in protein levels 
of the caspases in the RKO cells but not the HT115 cells 
(Figure 3C). We then examined the effect of altered NOV 
expression on the apoptosis and survival of CRC cells 
Table 2: NOV transcript levels in CRC
Category No. Means ± SE (copies) P-value
T/N Normal 174 22008  ±  6994
Tumour 359 437 ± 126 0.0024
Paired T-N Paired T-N 173 T-N:-21295 ± 7039 0.0029
Location Colon 212 689 ± 2108
Rectum 144 72.4 ± 48.10 0.0046
Differentiation Well-differentiated 71 669 ± 358
Moderately 
differentiated
207 131.8 ± 42.1 0.35
Poorly differentiated 35 1480 ± 780 0.094
Tumour stage T1 1  *
T2 27 53 ± 23.2
T3 111 558 ± 256 T2 vs T3: 0.052
T4 193 327 ± 136 T2 vs T4: 0.049
T1&2 28 51 ± 22.5
T3&4 304 304 ± 127 T1 & 2 vs T3 & 4: 
0.0056
Lymph node N0 169 354 ± 153
N1 94 435 ± 233 0.77
N2 69 374 ± 273 0.95
N1&2 163 409 ± 177 0.81
Metastasis M0 301 413 ± 128
M1 31 74 ± 37.1 0.012
TNM stage I 21 68 ± 29.2
II 144 405 ± 179 0.066
III 136 474 ± 212 0.060
IV 31 74 ± 37.1 0.91
II & III & IV 311 402 ± 124 0.0093
Note: There were some missing cases due to lack of record of relevant information, including 3 cases missed for location, 46 
cases for differentiation and 27 cases for TNM staging. For TNM staging, TNM III and IV groups had 167 cases including 
4 N0 cases which had distant metastases, while the rest were N1 or N2.
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using a flow cytometric assay (Figure 3D and 3E). There 
was no obvious effect on apoptosis seen in the CRC cells 
under general culture condition, i.e. DMEM supplemented 
with 10% foetal bovine serum (Figure 3D1 and 3D2). 
However, a better survival was seen in RKONOVkd cells 
when they were deprived of the serum. A decreased 
proportion of apoptotic cells (including both early and 
late apoptotic cells) were seen in RKO NOV knockdown 
cells (29.04%) compared to the control cells (48.56%). 
In contrast, an increased proportion of apoptotic cells 
were seen in HT115NOVexp cells (43.44%) compared to the 
HT115pEF cells (31.36%) (Figure 3D3 and 3D4).
NOV expression and chemoresistance of CRC
Further to the effect on proliferation and survival of 
CRC cells, we investigated the influence of altered NOV 
expression on chemotherapy resistance. 5-FU alone or in 
combination with other drugs, such as leucovorin calcium, 
oxaliplatin, irinotecan, bevacizumab and cetuximab, is 
considered as first-line or second-line chemotherapy 
regimen in CRC [19]. CRC cells were treated with 5-FU 
(100 μg/ml) for three days. RKO NOV knockdown cells 
exhibited a reduced response to the treatment of 5-FU, 
while NOV overexpression in HT115 cells enhanced the 
inhibition of cell growth (Figure 4A and 4B). 
We then examined the expression of NOV in CRC 
tumour samples from biopsies of patients who received 
Neo-adjuvant chemotherapy, using immunochemical 
staining. There were 22 tumour samples and 11 paired 
adjacent normal colon tissues. According to the post-
operative clinic-pathological assessment, three patients 
had a progressive disease (PD) after the neo-adjuvant 
chemotherapy; eight patients had stable disease (SD); 
nine patients had partial response (PR) and two patients 
had complete response (CR). Higher staining of NOV 
was seen in the tumours with CR to the chemotherapy, 
p = 0.078 vs. the SD tumours and p = 0.092 vs. the PD 
tumours (Figure 4C). Following a normalisation against 
NOV staining in the corresponding adjacent normal colon 
tissues, a stepwise increase was seen for the NOV staining 
in tumours with SD (p = 0.054), PR and CR tumours 
(p = 0.143) compared with its staining in the progressive 
tumours (Figure 4D).
JNK pathway in NOV-regulated cell 
proliferation, survival and invasion of CRC cells
Recent studies have shown the JNK pathway is 
involved in NOV-regulated or coordinated cellular functions. 
For example, JNK pathway has been shown to mediate 
NOV-induced CCL2 expression in rat brain astrocytes 
[20]. NOV enhances bone morphogenetic protein-4 
expression and bone nodule formation in osteoblasts, via 
integrin-linked kinase, p38, JNK, and AP-1 signalling 
pathways [21]. Following an initial assessment of signal 
transduction through MAPK pathways using a KinexTM 
antibody microarray (Supplementary Figure 4), changes 
Figure 1: Expression of NOV protein in CRC. (A) The expression of NOV protein in human CRC tumours were assessed using 
immunochemical staining in comparison with paired adjacent normal colon tissues. H&E staining of the same sample is also provided. 
The images were reduced from × 100 magnification. Small panels, inserted in main images, were reduced from a photo taken under 
× 400 magnification. (B) Semi-quantification of NOV staining in CRC tissues. Shown are average intensity of NOV staining in the tumours 
compared with its staining in the adjacent normal colorectal tissues. Error bars represent standard deviation. (C) Negative control, where 
samples were treated with secondary antibody only is included. 
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were observed in phosphorylation of ERK1/2 and JNK, 
but not p38, in the RKONOVkd and HT115NOVexp cells. To 
determine the possible signalling pathways mediating 
the effect of NOV, immunoprecipitation and Western blot 
were used to assess the effect of NOV on the threonine, 
serine and tyrosine phosphorylation of JNK and ERK in 
RKO and HT115 cells. The results indicated that tyrosine 
phosphorylation of JNK was increased in RKO NOV 
knockdown cells compared with control cells (P < 0.01) 
(Figure 5A), while threonine phosphorylation of JNK 
decreased in HT115NOVexp cells (P < 0.001) (Figure 5B). 
No difference was observed in the phosphorylation of 
threonine, serine and tyrosine residues of ERK in both 
RKO and HT115 cells (Figure 5A and 5B). The addition of 
JNK inhibitor Anthra (1 µM) blocked NOV knockdown-
promoted cell proliferation (Figure 5C). We then determined 
the expression of Caspase -3 and -8 in the RKONOVkd cells 
which were exposed to the Anthra for 24 hours. The 
resultant down-regulation of Caspase -3 and -8 in RKONOVkd 
cells diminished with the use of the treatment of Anthra 
(Figure 5E and 5F). Furthermore, NOV knockdown-
promoted invasiveness of RKO cells was also suppressed by 
the JNK inhibitor (Figure 5G). 
DISCUSSION
Our present study suggests that NOV is a putative 
tumour suppressor for CRC, as higher NOV expression 
was detected in the epithelial cells within normal colon 
tissue compared to CRC tumours. Furthermore, a higher 
expression of NOV was also observed in the colon tissues 
compared with rectum. A down regulation of NOV 
expression is evident in chronic myeloid leukaemia, 
glioma, malignant adrenocortical tumours and melanoma 
[18, 22–25] , whilst NOV has been found to be up 
regulated in human prostate cancer, chondrosarcomas, 
Wilms’ tumour and cervical cancer [16, 26–28]. Our 
study also linked increased local invasion of CRC tumours 
Figure 2: NOV expression in CRC cell lines and cancer cell invasion. (A) NOV expression in the CRC cell lines was examined 
using RT-PCR. (B) Knockdown and overexpression of NOV in CRC cell lines were verified using RT-PCR. (C) Corresponding changes 
of the NOV protein in the transfected cell lines were further confirmed using Western blot analysis. (D) Three independent transfections 
were performed for each cell line. Shown are NOV/GAPDH ratio using semi-quantitative analysis of the Western blot data. Error 
bars are standard error of mean. (E) An increased invasion was seen in the RKONOVkd cells compared with RKOpEF cells (p < 0.001). 
(F) NOV overexpression reduced the invasiveness of HT115 cells (p < 0.001). (G) The activation of MMPs were determined using a 
gelatine zymography. *** represents p < 0.001. Three independent experiments were performed. Shown are representative results, error 
bars represent standard deviations.
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(T3 and 4) with elevated levels of NOV transcript levels, 
though the IHC did not corroborate this. Another recent 
study assessed the expression of NOV in a cohort of 126 
CRC tumours, showing that higher expression in some 
CRC tumours was associated with poorer survival as 
well as local invasion [17]. In our current study however, 
a reduced expression of NOV was seen in CRC tumours 
compared with paired adjacent normal colon tissues. This 
is in line with findings from analyses of other GEO data 
(Supplementary Figure 1). Our current finding was also 
supported by immunochemical staining of NOV protein in 
CRC tumours together with paired adjacent normal colon 
tissues. Certainly, micro-dissected cancerous cells from 
CRC frozen sections and normal mucosa from normal 
colonic tissue (either paired or non-paired) and subsequent 
quantification of gene expression using real time PCR, 
gene expression micro-array or RNA sequencing will 
be helpful to settle this controversy. Overexpression of 
NOV has been shown in metastatic melanoma cells when 
compared with its expression in primary melanoma. 
The overexpression of NOV enhanced the adhesion of 
melanoma cells to laminin and vitronectin through an up 
Figure 3: NOV suppresses proliferation and survival of CRC cell lines. (A) Proliferation of CRC cell lines with altered 
expression of NOV was determined using an in vitro proliferation assay. The proliferation over a period of up to four days was assessed 
for RKONOVkd cells and HT115NOVexp cells in comparison with their corresponding control. Three independent experiments were performed. 
Shown are representative results, error bars represent standard deviations. *** represents p < 0.001, ** represents p < 0.01. (B) Expression 
of Caspase -3, -8 and -9 in the RKO and HT115 cells were examined using RT-PCR. (C) Western blots were employed to detect protein 
expression and cleavage of caspases-3, -8 and -9. Pro-caspase 3 is approximately 32kDa and is cleaved into 17kDa and 12 kDa subunits. 
Pro-caspase 8 is approximately 57kDa and can be cleaved into 43kDa, 41kDa and 18kDa subunits. Pro-caspase 9 was detected as bands 
around 45kDa, and subunits at sizes of approximately 35kDa and 25kDa following cleavage. (D) A flow cytometric apoptosis assay was 
employed to analyze the apoptotic populations in the CRC cell lines under normal culture condition using DMEM supplemented with 10% 
foetal bovine serum (C1:RKO and C2:HT115) or deprived from the serum (C3:RKO and C4:HT115). Q3 were healthy cells which were 
negative for both PI and annexin V-FITC. Counts in Q4 were early apoptotic cells that were only positive for Annexin V-FITC, while counts 
in Q2 were late apoptotic or dead cells which are positive for both PI and annexin V-FITC. (E) Shown are statistical analyses of three 
independent experiments determining apoptotic populations within CRC cells displaying altered expression of NOV. **p < 0.01. Error bars 
are standard deviations.
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regulation of integrin α7β1 and αVβ5 [29]. This contrasts 
to its reduced expression in primary melanoma, which is 
associated with promoted invasiveness of melanoma cells 
at primary sites [18]. This suggests that NOV is a putative 
tumour suppressor for CRC, and together with previous 
reported roles in different malignancies, that a differential 
role can be played by NOV in different organs and tissues. 
These contradictory findings in different malignancies 
also suggest that NOV plays diverse and dynamic roles 
during disease progression, which can be tissue specific 
or disease specific. 
CCNs are matricellular proteins and can be secreted 
into the extracellular matrix. Our immunochemical 
staining showed that NOV protein was mostly confined 
in the cytoplasm of epithelial cells and was reduced in 
the CRC cancer cells. NOV has been detected in culture 
medium, extracellular matrix (ECM) and at the cell 
membrane [30–32], whilst CCN1 has also been detected 
in culture medium [33]. Our previous study has shown 
confined staining of CCN4, CCN5 and CCN6 at the cell 
membrane in normal colorectal epithelial cells, while an 
increased staining of CCN4 and CCN6 was seen in CRC 
tumours [12]. A localization of CCN5 in nuclei was also 
observed in rat and human tissues [34]. 
To expand our understanding of the role played 
by NOV in CRC, we examined the influence of NOV 
on cellular functions of CRC cell lines. The altered 
expression of NOV resulted in contrasting effects on their 
proliferation and invasion, but elicited little effect on 
adhesion and migration. Corresponding changes were also 
seen in the activated MMP-2/-9 in the NOV knockdown 
and overexpression cells which were consistent with their 
contrasting impacts on the invasiveness of the two CRC 
cell lines. These results indicate that NOV mediates an 
inhibitory effect on the proliferation and invasion of CRC 
cells which is in line with the reduced expression observed 
in the CRC tumours and the corresponding implication for 
distant metastases. However, Udea et al showed that NOV 
was able to enhance invasiveness of other CRC cell lines 
(COLO205 and SW480) [17]. It suggested that a different 
molecular machinery underlying NOV related functions 
may be utilised in certain CRC tumour cells which is yet 
Figure 4: Reduced NOV expression and chemotherapy resistance of CRC cells. (A) Knockdown of NOV resulted in an 
enhanced resistance to the treatment of 5-FU, while the same 5-FU treatment achieved a greater inhibition rate in the HT115NOVexp cells 
compared to their respective controls. The inhibition rates were calculated for the cells treated with 5-FU against their corresponding 
untreated control cells. (B) Proliferative rates in untreated controls. Shown are representative results from three independent experiments. 
Error bars represent standard error of mean. * represents p < 0.05; ** represents p < 0.01. (C) NOV expression in CRC tumours and 
the possible link with chemotherapy resistance. IHC was performed for NOV protein in FFPE specimens from diagnostic biopsies. 
PD = progressive disease; SD = stable disease; PR = partial regression; CR = complete regression. Shown is the intensity of NOV IHC 
staining, determined using ImageJ and background subtracted. (D) Normalized intensity of NOV IHC staining and chemotherapy resistance 
in CRC. NOV staining in tumours was normalised against their paired adjacent normal colon tissues.
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to be investigated. For instance, differential expression 
profile of NOV interacting molecules may divert the 
response in different cell lines or cancers. 
In addition to the effect on cell proliferation, the 
altered expression of NOV did influence the survival of 
CRC cells under stress. In the present study, the CRC cells 
were cultured in a medium with a deprivation of serum 
which generally induced apoptosis after a culture period 
of 48 hours. The loss of NOV resulted in a better survival 
in the RKO cells while more apoptotic cells were seen in 
the HT115 NOV overexpression cells. These observations 
supported by a reduced expression of caspase-3 and -8 
prompted further investigation of a possible link between 
reduced expression of NOV and chemoresistance. 
Fluorouracil (5-FU)-based chemotherapy is 
generally considered as the first-line treatment for 
advanced CRC [35]. Response rates to 5-FU treatment 
are between 10–20% in the advanced CRC [36], and a 
better response rate has been reported using combined 
chemotherapy regimens of 5-FU and oxaliplatin which 
is 40–50% [37]. In the current study, we examined 
the responses to 5-FU in CRC cell lines with altered 
expression of NOV. A reduced effect of 5-FU was seen in 
RKO NOV knockdown cells while a contrasting change 
was observed in HT115 NOV overexpression cells.  
A further examination of NOV expression in a 
cohort of biopsy samples from patients who received 
neo-adjuvant chemotherapy, we observed that CRC 
tumours with reduced NOV expression tended to be less 
responsive, though not significantly so, to neo-adjuvant 
chemotherapy. Interestingly, a ratio of NOV staining in 
CRC tumours against their paired adjacent normal colon 
tissues showed a stepwise increase when the tumours were 
more responsive to the chemotherapy. Its predictive value 
should be further investigated in a large cohort of CRC 
patients who received chemotherapy. Quantitative analysis 
of NOV transcripts or protein in micro-dissected tumour 
together with paired adjacent normal colon tissues will 
provide more precise confirmation of the findings in the 
present study. 
NOV has been shown to inhibit Wnt/β-catenin 
signalling pathway through the suppression of bone 
morphogenetic protein-2 (BMP-2) activity [38]. In certain 
myogenic cells the NOV-Notch association exhibits 
Figure 5: JNK pathway in the NOV-regulated proliferation, survival and invasion of CRC cell lines. Activation of JNK 
and ERK was determined from the phosphorylation of their tyrosine, serine and threonine residues by immunoprecipitation and Western 
blot (A, RKO and B, HT115). Positive controls consisted of RKO and HT115 wild type cells treated with 10 mM Sodium orthovanadate and 
0.8% (vol/vol) hydrogen peroxide for 10 minutes. JNK inhibitor diminished the pro-proliferative effect of NOV knockdown in RKO cells 
over a period of three days (C) and four days (D). The NOV-regulated expression of Caspase -3 and -8 was also blocked by the addition 
of JNK inhibitor (E, RT-PCR and F, Western blot). (G) NOV knockdown promoted invasion in RKO cells was suppressed by the JNK 
inhibitor. * represents p < 0.05, ** represents p < 0.01 and *** represents p < 0.001. Error bars represent standard error of mean. 
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a positive effect on the Notch signalling pathway and 
suppresses cellular differentiation [39]. Recent studies 
have shown that JNK is also involved in NOV mediated 
effects on cellular functions. For example, NOV 
promoted CCL2 production by Rho/ROCK/JNK/NF-
κB pathway in rat brain astrocytes, and played a role in 
neuro-inflammation [20]. NOV was also able to promote 
bone formation by up-regulating BMP-4 expression in 
osteoblasts through integrin-linked kinase, p38, JNK, and 
AP-1 signalling pathways [21]. To assess the involvement 
of JNK in the NOV-induced effect on CRC, we determined 
the activation of JNK in the NOV knockdown and 
overexpression cells. Tyrosine phosphorylation of JNK 
was increased in RKO NOV knockdown cells, while a 
reduced threonine phosphorylation of JNK was seen in 
HT115 NOV overexpression cells. More interestingly, 
an addition of small inhibitor targeting JNK eliminated 
the effect of NOV knockdown on the proliferation 
and invasion with corresponding changes seen in the 
expression of caspase-3/-8 and MMP-2/-9. Furthermore, 
the JNK inhibitor also prevented chemoresistance in the 
RKO NOV knockdown cells. It suggests that tyrosine 
phosphorylated JNK and NOV have joint potential in 
the prediction of chemoresistance. Targeting these two 
molecules could be warranted, to provide personalised 
disease management for patients with CRC.  
In summary, NOV is down-regulated in CRC 
tumours which is associated with disease progression. 
NOV inhibits the proliferation and invasion of CRC cells 
by regulating caspase-3/-8 and MMP-2/-9 through JNK 
pathway. NOV together with JNK are promising predictive 
markers and therapeutic targets for chemoresistance and 
personalized disease management of CRC.
MATERIALS AND METHODS
Cell lines and culture conditions
Human colon cancer cell lines RKO and HT115 were 
purchased from the American Type Culture Collection 
(ATCC, Manassas, VA) and incubated at 37°C, 5% CO2 
and 95% humidity. Wild-type cells were maintained in 
Dulbecco’s modified Eagle’s medium supplemented with 
10% fetal calf serum (PAA Laboratories Ltd., Somerset, 
UK), amphotericin B, penicillin and streptomycin (Sigma-
Aldrich Inc., Poole, Dorset, UK). Transfected cells were 
maintained in regular medium containing 0.5 μg/ml 
blasticidin. JNK inhibitor, Anthra, was purchased from 
Tocris Bioscience (Bristol, UK).
Human colorectal cancer tissues
Human CRC tissues including tumours (n = 359) 
and adjacent background tissues (n = 174) were collected 
immediately after surgery and stored at −80°C. Total RNA 
extraction was performed for this cohort of frozen tissues. 
All protocols were approved by the Beijing Friendship 
Hospital Research Ethical Committee. Written consents 
were obtained from the patients.
RNA isolation, reverse transcription-polymerase 
chain reaction (RT-PCR) and quantitative real 
time PCR (QPCR) 
Total RNA was extracted from confluent cells 
in a 25 cm2 flask using a RNA isolation (TRI) reagent 
following the standard protocol (Sigma-Aldrich, Dorset, 
UK). Fresh frozen tissues were also first homogenized in 
TRI reagent using a hand held homogenizer. First strand 
cDNA was synthesized from 1 µg RNA using a reverse 
transcription kit (BioRad, UK). NOV mRNA expression 
in CRC tissues was determined using real time PCR and 
an Ampliflor™-based PCR method, in which a 6-carboxy-
fluorescine-tagged Uniprimer™ (Biosearch Technologies, 
Inc.) was used as a probe together with a pair of target 
specific primers. The reverse primer contained a 
Z-sequence (actgaacctgaccgtaca) which is complimentary 
to the unique sequence in the Uniprimer. Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) was used as a 
housekeeping gene. Primers used in the present study are 
listed in Table 1.
Immunochemical staining of NOV in CRC 
Formalin Fixed Paraffin Embeded (FFPE) 
specimens
FFPE sections including 45 CRC tumours and 
27 adjacent normal colorectal tissues were provided 
by the Beijing Friendship Hospital. FFPE specimens 
from biopsies in a group of patients who received neo-
adjuvant chemotherapy at the Beijing Friendship Hospital 
were also used for assessing the expression of NOV by 
immunochemical staining. All patients in this group had 
liver metastases at the diagnosis. The tissue samples were 
from biopsies before the neo-adjuvant chemotherapy. 
In total, there were 22 tumour samples with 11 tumours 
having paired adjacent normal colon tissues in this group 
of specimens. Response to neo-adjuvant chemotherapy 
was evaluated using RECIST criteria version 1.1 [40]. All 
protocols were approved by the Beijing Friendship Hospital 
Research Ethical Committee. Written consents were 
obtained from the patients. A verification and HE staining 
were undertaken by pathologists at the Beijing Friendship 
Hospital. In brief, IHC staining of NOV was performed 
for these FFPE specimens following a standard procedure. 
Following a de-waxing and rehydration in PBS, antigens 
were retrieved using 1mM EDTA (pH 8.0) in a microwave 
for 20 minutes. After cooling in tap water and washing in 
PBS, the sections were then blocked in 5% horse serum for 
2 hours, before an overnight incubation at 4oC with anti-
NOV antibody (0.5 µg/ml, ab137677, Abcam). A secondary 
biotinylated antibody and the avidin biotin complex was 
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used to detect NOV expression in accordance with the 
Vectastain Universal Elite ABC kit protocol (Vector 
Laboratories, Peterborough, UK), and the end product 
was developed with 3,3′-diaminobenzidine (DAB). The 
sections were then counterstained with Gill’s hematoxylin. 
The intensity of staining was independently assessed by the 
authors using ImageJ (http://imagej.nih.gov/ij/).
Construction of ribozyme transgene targeting 
human NOV and the establishment of 
corresponding stable transfectants
Anti-human NOV hammerhead ribozymes were 
designed and generated using Zuker RNA mFold program 
[41]. The ribozymes were produced and cloned into the 
pEF6/V5-His TOPO vector (Invitrogen, Paisley, UK). 
The full-length coding sequence of human NOV was 
amplified from a human placenta cDNA library. The NOV 
coding sequence (CDS) was also cloned into the pEF6/
V5-His TOPO vector. Constructed ribozyme transgenes, 
NOV expression vector and empty plasmid vector were 
transfected into RKO and HT115 cells, respectively, 
using an Easyject Plus electroporator (EquiBio, Kent, 
UK). After one week of selection in DMEM containing 
5 μg/ml blasticidin followed by another week of culture 
in DMEM containing a maintenance concentration of 
0.5 μg/ml blasticidin, the transfected cells were verified 
for the expression of NOV and were subsequently used for 
the following experiments. 
Western blot analysis
Following lysis of cells, the protein concentration 
was determined using the DC protein assay kit (Bio-
Rad) and the ELx800 spectrophotometer (Biosearch 
Technologies, Inc.). Equal amount of each protein samples 
were separated using SDS-PAGE followed by electro 
blotting onto a nitrocellulose membrane. The proteins 
were then probed with the anti-NOV antibody (1:2,000, 
Abcam Ltd.) and anti-GAPDH antibody (1:2,000, Santa 
Cruz Biotechnology, Inc.), as a house keeping gene 
control, followed by a peroxidase-conjugated secondary 
antibody (1:2,000, Sigma). Protein bands were visualized 
using a chemiluminescence detection kit (Luminata, 
Millipore) and photographed using a Syngene imager 
(Syngene International Ltd.).
KinexTM antibody microarray
To prepare cell lysates for use with the KinexTM 
antibody microarray (Kinexus Bioinformatics Corporation, 
Vancouver, Canada), two T75 flasks of cells were grown 
to approximately 90% confluence. The cells were washed 
twice with PBS before adding 20 ml of DMEM which 
was supplemented with 2% FCS. Following a 2-hour 
incubation at 37oC, the cells were lysed in a lysis buffer 
containing 100mM tris, 10% 2-mercaptoethanol, 1% 
NP-40, 50 mM NaFI, 2 mM 4-(2-aminoethyl) 
benzenesulfonyl fluoride (AEBSF), 14 µM E-64, 130 µM 
bestatin, 1 µM leupeptin, 0.3 µM aprotinin, and 1mM EDTA. 
In vitro cell growth assay
The IC50 of 5-Fluorouracil (5-FU) was determined 
using a colorimetric method to quantify cells [42]. In brief, 
3,000 cells were seeded into two 96-well plates in culture 
medium and with different concentrations of 5-FU. Cells 
were incubated for 1 and 3 days before being fixed with 
4% formaldehyde, and stained with 0.5% crystal violet. 
The stain was then dissolved in 10% acetic acid prior to 
the colorimetric detection of cell density using the ELx800 
spectrophotometer at a wavelength of 540 nm.
Table 1: Primer sequences
Gene Forward primers (5′-3′) Reverse primer (5′-3′)
GAPDH GGCTGCTTTTAACTCTGGTA GACTGTGGTCATGAGTCCTT
GAPDH (Q-PCR) CTGAGTACGTCGTGGAGTC ACTGAACCTGACCGTACACAGAGATGACCCTTTTG
NOV CTCCAAGAAAAGTTGAGGTG CTGGCTTCTTGACTATTTGC
NOV (Q-PCR) CTGTGAACAAGAGCCAGAG ACTGAACCTGACCGTACACTTGAACTGCAGGTGGAT
NOV ribozyme CTGCAGCGCTGAGTCGCAGCGACCTGT
CCCAGGACTGATGAGTCCGTGAGGA
ACTAGTGCCTTTGCCTGACCTTCCTGCTTCTC
CATTTCGTCCTCACGGACT
NOV CDs ATGCAGAGTGTGCAGAGCA CATTTTCCCTCTGGTAGTCTTCA
Caspase3 GGCGTGTCATAAAATACCAG ACTGAACCTGACCGTACAACAAAGCGACTGGATGAA
Caspase8 AAGCCCAAGCTCTTTTTC ACTGAACCTGACCGTACAGTTACTGCCAGGGGACTC
Caspase9 GGCTGCTTTTAACTCTGGTA GACTGTGGTCATGAGTCCTT
AQ1
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In vitro invasion assay
Invasion assays were performed following a 
previously described procedure [43]. Transwell inserts 
with 8 μm pores were pre-coated with 50 μg of Matrigel 
Matrix Basement Membrane (BD Bioscience, Oxford, 
UK) and air-dried. Following rehydration, 30,000 cells 
were seeded to each insert and also control wells on a 
24-well plate.  After an incubation of 72 hours, cells that 
had migrated through the matrix to the other side of the 
insert were fixed, stained, counted and then dissolved 
with 10% acetic acid. Cell density was determined by 
reading the absorbance at 540 nm with the ELx800 
spectrophotometer.
Cell-matrix adhesion assay
The cell-matrix adhesion assay was conducted as 
previously described [43]. A 96-well culture plate was pre-
coated with 5 μg of Matrigel and air-dried. The Matrigel 
was rehydrated before seeding 30,000 cells to each well. 
Non adherent cells were washed off using a PBS buffer 
following an incubation of 40 minutes. Adherent cells 
were then fixed and stained. The number of adherent cells 
were counted before the absorbance of the crystal violet 
stain was determined by dissolving in 10% acetic acid and 
results were read on a ELx800 spectrophotometer.
Wound healing assay
The assay was performed as previously described 
[43]. Cells were seeded onto 24-well plates and incubated 
overnight. The monolayer of cells was scraped with a 
10μl pipette tip. The migration of cells was monitored 
and photographed using the EVOS system, a fluorescent 
inverted microscope system equipped with an on-stage 
incubator (Life Technologies Ltd, Paisley, UK), and the 
migration of cells was determined using ImageJ.  
Immunoprecipitation (IP) and western bolt 
analysis
The cells were lysed and the protein concentration 
was determined following the aforementioned procedure. 
Equal amounts of protein samples (160μg/80μl) were 
incubated with the anti-phosphotyrosine antibody 
(PY20, 1:500, Santa Cruz Biotechnology, Inc.), anti-
phosphoserine antibody (p-Ser, 1:500, Santa Cruz 
Biotechnology, Inc.), and anti-phosphothreonine antibody 
(p-Thr, 1:500, Santa Cruz Biotechnology, Inc.) at 4°C for 1 
hour respectively, followed by the addition of 15μl protein 
A/G plus-agarose beads (Santa Cruz Biotechnology, Inc.) 
and an incubation of 1 hour. The samples were washed 
with SDS-free lysis buffer twice before they were boiled 
with 1× sample buffer (Sigma). Proteins were probed with 
the anti-JNK antibody (1:500, Santa Cruz Biotechnology, 
Inc.), and anti-ERK antibody (1:500, Santa Cruz 
Biotechnology, Inc.), followed by a peroxidase-conjugated 
secondary antibody (1:2,000, Sigma). Protein bands 
were visualized using a chemiluminescence detection kit 
(Luminata, Millipore) and photographed using a Syngene 
imager (Syngene International Ltd.).
Gelatin zymography assay
To prepare conditioned medium from cancer cells, 
2 × 106 cells were seeded into a T25 flask. Following 
overnight culture, the cells were washed once with 1 × 
PBS followed by another wash with serum-free DMEM, 
and were then incubated in serum-free DMEM medium for 
6 hours. The conditioned medium was collected. Samples 
were prepared in non-reducing sample buffer (0.625 mM 
Tris-HCl, 10% glycerol, 2% SDS, and 2% bromophenol 
blue), and were then separated using SDS-PAGE 
containing 0.25% gelatin (Sigma-Aldrich Inc, USA). The 
gels were re-natured twice using washing buffer (2.5% 
triton X-100 and 0.02% NaN3) and then incubated for 48 
hours at 37°C in an incubation buffer (50 mM Tris-HCl, 
5 mM CaCl2, and 0.02%NaN3). The gels were stained 
with coomassie blue for 30 minutes and de-stained twice 
with de-stain buffer (10% acetic acid and 25% ethanol). 
The gels were then photographed using a Syngene imager 
(Syngene International Ltd.).
Flow cytometric analysis of apoptosis
For apoptosis analysis, 8x105 cells were seeded into 
T25 flasks and cultured in DMEM supplemented with 10% 
FCS, while 2 × 106 cells were seeded into T25 flasks which 
were cultured in serum free DMEM.  Following 48-hour 
culture, both adherent and cells present in the medium 
were harvested. The apoptotic population was determined 
using the Annexin V kit (Santa Cruz Biotechnology) and 
analyzed using PartecCyFlow® SL flow cytometry and the 
accompanying FloMax software package (Partec GmbH, 
Münster, Germany) [44].
Statistical analysis
Statistical analyses were performed using SPSS 
(IBM Corporation, Armonk, NY). T-test and Mann 
Whitney tests were used for normally distributed data and 
non-parametric data respectively. A p-value of < 0.05 was 
considered statistically significant.
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